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In Brief
LRRK2 is a serine/threonine kinase
associated with Parkinson disease.
LRRK2 phosphorylates Rab8a (pRab8a),
which subsequently binds effector
RILPL2 and regulates ciliogenesis.
Waschb€usch et al. describe the structure
of the pRab8a:RILPL2 complex and how
phosphothreonine is recognized by an
arginine from RILPL2. The structure
reveals how LRRK2 assembles a
trafficking complex..
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SUMMARY
Rab8a is associated with the dynamic regulation of
membrane protrusions in polarized cells. Rab8a is
one of several Rab GTPases that are substrates of
leucine-rich repeat kinase 2 (LRRK2), a serine/threo-
nine kinase that is linked to Parkinson’s disease.
Rab8a is phosphorylated at T72 (pT72) in its switch
2 helix and recruits the phospho-specific effector
RILPL2, which subsequently regulates ciliogenesis.
Here, we report the crystal structure of phospho-
Rab8a (pRab8a) in complex with the RH2 (RILP ho-
mology) domain of RILPL2. The complex is a hetero-
tetramerwithRILPL2 forming a centrala-helical dimer
that bridges two pRab8a molecules. The N termini
of the a helices cross over, forming an X-shaped
cap (X-cap) that orients Arg residues from RILPL2 to-
ward pT72. X-cap residues critical for pRab8abinding
are conserved in JIP3 and JIP4, which also interact
with LRRK2-phosphorylated Rab10. We propose a
general mode of recognition for phosphorylated Rab
GTPases by this family of phospho-specific effectors.
INTRODUCTION
Parkinson’s disease (PD) is a disorder of the CNS that manifests
as a progressive degeneration of motor mobility, loss of balance,
and tremors. Features of the pathology include loss of dopami-
nergic neurons in the midbrain and the presence of protein ag-
gregates termed Lewy bodies, composed mainly of a-synuclein,
in surviving neurons (Fahn, 2003). About 10% of cases have a
genetic basis, with the most common gene being the leucine-
rich repeat kinase 2 (LRRK2) (Schulte and Gasser, 2011). The
gene product is a 2,527-residue (286 kDa) protein with multiple
domains belonging to the ROCO family that is involved in regu-
lation of autophagy, mitochondria, and Golgi dynamics (Roosen
and Cookson, 2016). The kinase domain, located near the C ter-
minus, phosphorylates itself and other proteins at serine/threo-
nine residues (Greggio et al., 2008; Schulte and Gasser, 2011;
Steger et al., 2016). Preceding the kinase domain, there is a
Ras-like ROC domain (Ras of complex) followed in tandem by
a COR domain (C-terminal of Ras). The ROC domain binds nu-
cleotides (GTP/GDP) and is distantly related to the Rab family
of small GTPases. The ROC-COR tandem domains regulate
LRRK2 activity, and numerous missense mutations have been
localized to these regulatory and kinase domains (Hui et al.,
2018; Paisan-Ruiz et al., 2004; Zimprich et al., 2004). In addition
to early onset forms of PD associated with autosomal dominant
mutations, LRRK2 is also linked to late-onset sporadic cases of
PD (Bardien et al., 2011).
Insight into LRRK2 functions has progressed significantly
with the finding that a subset of small GTPases that include
Rab8 and Rab10 are physiological substrates of the enzyme
(Steger et al., 2016; West and Cookson, 2016). Rabs comprise
the largest group (70 members) of the Ras superfamily, and
they cycle between an active GTP bound and inactive GDP
form to regulate membrane trafficking in eukaryotic cells (Huta-
galung and Novick, 2011). The nucleotide-bound state of Rabs
is regulated by GTPase-activating proteins (GAPs) and GTP/
GDP exchange factors (GEFs), and active Rabs migrate to
distinct sub-cellular compartments where they recruit cytosolic
effector proteins. The ‘‘switch’’ regions of Rabs, termed switch
1 and 2, undergo local conformational changes that enable
recruitment of GTP-specific effectors, which subsequently con-
trol processes, such as vesicle formation/fusion, motility, and
other aspects of cell dynamics (Khan and Menetrey, 2013).
LRRK2 phosphorylates Rab8a at T72 and Rab10 at T73,
conserved threonine residues located on the a-helical switch
2 region. This post-translational modification modulates inter-
actions between Rabs and their binding partners (Steger
et al., 2016, 2017). For example, it inhibits interaction with
Rab GDP dissociation inhibitors (GDIs) and Rabin-8, a GEF for
Rab8a (Steger et al., 2016). LRRK2 phosphorylation of Rab8a
and Rab10 also promoted interaction with two poorly studied
scaffolding proteins termed RILPL1 (Rab interacting lysosomal
protein-like 1) and RILPL2 (Steger et al., 2017), that were previ-
ously implicated in regulating ciliogenesis (Schaub and Stearns,
2013). RILPL1 and RILPL2 belong to the RILP family of effector
proteins (Jordens et al., 2001). Unlike RILPL1 and RILPL2, RILP
was not observed to interact with LRRK2 phosphorylated
Rab8a or Rab10 (Steger et al., 2017); however, it is a known
effector for Rab7a GTPase (Cantalupo et al., 2001). A recent
study has suggested that RILP may bind more strongly to
Rab7a phosphorylated at the equivalent site to LRRK2 by the
related LRRK1 kinase (Hanafusa et al., 2019). Cellular studies
Structure 28, 1–12, April 7, 2020 Crown Copyright ª 2020 Published by Elsevier Ltd. 1
This is an open access article under the CC BY license (http://creativecommons.org/licenses/by/4.0/).
Please cite this article in press as: Waschb€usch et al., Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2, Struc-
ture (2020), https://doi.org/10.1016/j.str.2020.01.005
have confirmed that LRRK2 blocks ciliogenesis by phosphory-
lating Rab8a and Rab10 and promoting RILPL1 interaction
(Dhekne et al., 2018). RILPL1 and RILPL2 are homologous
and were shown to interact with LRRK2-phosphorylated
Rab8a and Rab10 via a C-terminal phospho-Rab binding
domain that encompasses a conserved region of the protein.
This region of the protein is also known as the RILP homology
domain 2 (RH2) and encompasses residues 291–356 on RILPL1
and residues 130–201 on RILPL2. RILPL1 and RILPL2 also
contain an N-terminal RH1 domain that binds to the globular
tail domain (GTD) of myosin Va (Lise et al., 2009).
Upstream of the kinase, it has been shown that Rab29 recruits
LRRK2 to the Golgi and activates the kinase, leading to an
enhanced phosphorylation of substrate Rab GTPases, as well
as increased autophosphorylation (Fujimoto et al., 2018; Liu
et al., 2018; Purlyte et al., 2017). Rab32 is not a target for the
kinase but it interacts with LRRK2 and regulates its sub-cellular
localization (Waschbusch et al., 2014). These findings place
LRRK2 at the center of a Rab signaling cascade that is key to
understanding the molecular pathways that underpin PD.
Recently, PPM1H has been identified as the phosphatase that
counters LRRK2 activity via a phosphatase family small interfering
RNA screen (Berndsen et al., 2019). PPM1H efficiently hydrolyses
the phosphate frompRab8a and pRab10 substrates in vitro and in
cells. Reversible phosphorylation provides a means of tuning the
strength of interactions between Rab GTPases and their interact-
ing proteins. Here, we describe the crystal structure of T72 phos-
phorylated Rab8a(GTP) in complex with a minimal phospho-Rab
binding domain of RILPL2 at 1.8 A˚ resolution. The structure re-
veals that the phosphothreonine (pT72) is recognized by a
conserved arginine from the RILP family of proteins. Moreover,
RILPL2-related proteins JIP3 and JIP4 interact with pT73-Rab10
suggesting a general mechanism for phospho-specific recogni-
tion of effectors by Rab GTPases.
RESULTS
Overall Structure of the pRab8a:RILPL2 Complex
For these studies we utilized a mutant of the globular G-domain
of Rab8a (Q67L, residues 1–181) that binds GTP constitutively.
Descriptions of the in vitro kinase reaction and subsequent purifi-
cation of pRab8a are described in Figures S1 and S2. Full-length
RILPL2 complexes failed to crystallize, but the phospho-Rab
binding domain of RILPL2 (residues 129–165) yielded crystals in
complex with pRab8a. This region is the minimal RH2 motif with
high sequence similarities to all members of the RILP effector
family. Crystals of the complex diffract to 1.8 A˚ resolution
(Table 1). The complex of pRab8a(GTP):RILPL2 is organized as
a heterotetramer in the asymmetric unit (Figures 1A and 1B),
with a central parallel a-helical dimer of the phospho-Rab binding
domain of RILPL2 bridging two molecules of pRab8a via hydro-
phobic and polar interactions (Figure 1C). As depicted by the
domain organization of RILPL1/2 (Figure 1D), the topology of
the complex on Golgi membranes would be consistent with the
RH1 domain of RILPL2 (1–106) oriented above the complex in
the orientation shown in Figure 1A to enable interactions with
the GTD of MyoVa. Both molecules of pRab8a in the complex
have GTP in the nucleotide pocket and their switch 1 and 2
conformations resemble the structure of active Rab8a (PDB:
4lhw; Guo et al., 2013). Each pRab8a molecule interacts with
both a helices of the effector, burying approximately 625 A˚2 of
surface area at each interface. The dual a-helical interactions
are restricted to the N-terminal segment of RILPL2. As the coiled
coil extends toward the C termini, a single a helix interacts with
each Rab monomer by interfacing with switch 1 and strand b2
of the interswitch region (Figure 1E). The C termini of pRab8a
(177–207) and RILPL2 (160–211) would reside proximal to the
membrane, as indicated with dashed lines following helix a5 of
Table 1. Crystallographic Data and Refinement Statistics
Data Collection
Beamline NECAT APS, 24-ID-E
Wavelength (A˚) 0.9792
Space group P 21 21 21
Cell dimensions
a, b, c, (A˚) 60.333, 71.509, 114.784
Resolution (A˚) 53.41–1.767 (1.83–1.767)
Total reflections 324,590 (29,329)
Unique reflections 49,201 (4,719)
Completeness (%) 99.55 (96.33)
<I/s> 16.4 (1.69)
Multiplicity 6.6 (6.2)
Rmerge 0.06877 (0.9488)
Rmeas 0.07469 (1.036)
Rpim 0.02883 (0.4097)
CC1/2 0.999 (0.649)
Refinement
No. of reflections for Rwork 49,193 (4,718)
No. of reflections for Rfree 2,419 (241)
Rwork 0.1789 (0.2882)
Rfree 0.2105 (0.3049)
No. of non-hydrogen atoms 3,832
Macromolecules 3,401
Ligands 72
Solvent 359
Protein residues 416
RMSD
Bond lengths (A˚) 0.007
Bond angles () 0.91
Average overall B factor 36.54
Mean B factors (A˚2)
Protein 35.84
Ligand 29.72
Water 44.53
Ramachandran analysis (%)
Favored 97.24
Allowed 2.76
PDB: 6rir
Values in parentheses in the column on the right correspond to the
statistics in the highest-resolution bin. RMSD, root-mean-square devia-
tion. Rmerge = Shkl SjrIhkl,j  <Ihkl>r/Shkl Sjhkl,j. Rwork = ShklrFo,hkl 
Fc,hklr/ShklFo,hkl.
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Figure 1. Structure of pRab8a in Complex with the Phospho-Rab Binding Domain of RILPL2
(A) Heterotetrameric assembly of two pRab8a molecules bridged by a central a-helical dimer of the phospho-Rab binding domain of RILPL2 (129–165). The two
chains of RILPL2 are in magenta and dark yellow. For pRab8a, switch 1 is shown in blue, switch 2 in red.
(legend continued on next page)
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pRab8a (Figure 1A). In the ensuing discussions, the acronyms
‘‘RL2’’ and ‘‘R8’’ will be used in superscript format to denote
RILPL2 and Rab8a residues, respectively.
The affinity of the interaction between pRab8a and the phos-
pho-Rab binding domain (129–165) of RILPL2 was evaluated
by isothermal titration calorimetry (Figure 1F, Left). The experi-
ment revealed a Kd = 3.3 mM (±0.5) for the interaction, which
indicates a relatively weak affinity that is similar to other physio-
logical Rab:effector complexes (Khan and Menetrey, 2013).
RILPL2 is a preformed dimer in solution, as indicated by static
light scattering coupled to gel filtration chromatography (Fig-
ure S2). There were no detectable interactions between non-
phosphorylated Rab8a(GTP) and RILPL2 (Figure 1F, Right).
Phosphorylated Switch 2 of Rab8a Interacts with an
‘‘X-cap’’ Region of RILPL2
The N termini of the RILPL2 dimer (N129RL2-T134RL2) cross
over in an extended conformation preceding the first a-helical
turn, forming an X-shaped cap (X-cap) over the coiled coil
(Figures 2A and 2B). The X-cap facilitates interactions of
both monomers of RILPL2 with a single phosphorylated switch
2 of pRab8a. This X-cap contains two conserved arginines
(R130RL2 and R132RL2) that previous mutagenesis analysis
Figure 2. Structural Details of pT72 Recogni-
tion by the X-cap of RILPL2
(A) View of an interface between pRab8a and the
dimer of RILPL2.
(B) Stick model of the interactions at the X-cap of
RILPL2.
(C) Electron density (2Fo  Fc, 1.2s) at the site of
pT72 (chain A) binding to R132RL2 (chain D,
magenta). The side chain of L135RL2 from chain C of
RILPL2 lies within van der Waals contact (4 A˚) of the
b-branched methyl group of pT72.
(D) Electrostatic surface rendering of the X-cap.
Blue is positive and red is negative, while switch 1
and 2 of pRab8a are ribbons with key residues
represented as sticks.
(B) View of the complex down the 2-fold axis of the heterotetramer, 90 relative to orientation in (A).
(C) Stick model of the RH2 domain of RILPL2. Rabs are stripped from the complex in this view, except for short segments of switch 1 and switch 2 (gray sticks).
(D) Domain organization of RILPL1/2 showing the RH domains and their interacting partners. The sequence corresponds to RILPL2.
(E) Simplified representation of the Rab:RILPL2 interface showing contacts between one molecule of Rab8a and the dimer of RILPL2. Polar interactions are
indicated in dotted blue lines. Switch 1 (Sw1) and switch 2 are indicated.
(F) Isothermal titration calorimetry analyses of the interactions between pRab8a and the phospho-Rab binding domain of RILPL2. Left, titration of RILPL2
(residues 129–165) into pRab8a(GTP). Right, titration of RILPL2 into Rab8a(GTP).
showed were required for interaction
with pRab8a (Steger et al., 2017). Inti-
mate contacts within the X-cap include
reciprocal backbone hydrogen bonds
between residues R132RL2-Phe133RL2
that resemble a short antiparallel b sheet
(Figure 2B). The phosphate moiety from
pT72 interacts with the guanidino group
(NH1/NH2) of R132RL2 on both sides of
the symmetric complex, with O/N dis-
tances between 2.5 and 2.9 A˚ (Figure 2C).
In contrast to these direct electrostatic
and hydrogen-bonding interactions, the side chain of
R130RL2 is more distant from pT72 (>6 A˚). An electrostatic
surface map of RILPL2 reveals the strongly positive charges
at the X-cap that enable recognition of pRab8a (Figure 2D).
In addition to electrostatic contacts, the X-cap residue
F133RL2 contributes to a complementary hydrophobic inter-
face with F70R8 and I73R8 from switch 2. The side chain of
T134RL2 acts as a capping residue by nucleating the a helix
via a hydrogen bond (3.2 A˚) to the backbone NH of
E137RL2. Therefore, the term X-cap is appropriate for this
region of RILPL2.
Mutational Analyses of the Binding Interface
The contribution of RILPL2 residues to complex formation with
pRab8a was evaluated bymutagenesis. LRRK2-phosphorylated
Rab8a was subjected to co-immunoprecipitation studies in cells
using wild-type and mutant forms of full-length RILPL2. For
these studies a pathogenic LRRK2[R1441G] mutant was overex-
pressed to ensure maximal phosphorylation of Rab8a. We also
treated cells with and without a potent and selective LRRK2 in-
hibitor termed MLi-2 (Fell et al., 2015) for 90 min to induce
dephosphorylation of Rab8a and, therefore, block association
with RILPL2 (Figures 3A and S3). These results revealed that
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Figure 3. Mutational Analyses Reveal Hotspots of pRab8a:RILPL2 Interactions
(A) HEK293 cells were transiently transfected with constructs expressing Flag-LRRK2[R1441G], HA-Rab8a and WT or mutant RILPL2-GFP. At 48 h post
transfection, cells were treated with ±500 nM MLi-2 for 90 min and then lysed. Upper panel, labeled IP:GFP: RILPL2-GFP was immunoprecipitated using GFP
(legend continued on next page)
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all mutations of R132RL2, which directly interacts with pT72,
abolished the interaction with pRab8a in cells. The exquisite
specificity of this contact is reflected by the R132KRL2 mutation,
which was sufficient to abolish the interaction (Figure 3A). Muta-
tion of K149RL2—which forms a salt bridge with D44R8 (switch
1)—also abolishes the interaction between RILPL2 and pRab8a.
This interaction, as well as hydrophobic packing of I41R8 against
the RILPL2 a-helical dimer, presumably encodes GTP-depen-
dent switch 1 specificity. Modest effects were observed with
mutations of R139RL2 and L135RL2, which form contacts with
switch 2 adjacent to the R132RL2:pT72 interaction. L135 packs
against the b-branched methyl substituent of pT72, while R139
forms a hydrogen bond with the backbone carbonyl oxygen of
pT72 (Figures 2A and 2C).
One apparent inconsistency between the structure and the
mutagenesis experiments is the contribution of R130RL2 toward
complex formation. Mutational studies reveal that R130QRL2
(Figure 3A), as well as R130KRL2, R130ERL2, and R130ARL2 (Fig-
ure S3), severely compromise interactions with pRab8a,
although to a lesser extent than R132RL2 mutants. As previously
mentioned, the side chain of R130RL2 lies more than 6 A˚ away
from pT72. There are two mechanisms by which the guanidino
group of R130RL2 could contribute to complex formation.
One is through long-range electrostatic interactions with pT72.
A second mechanism may be an indirect stabilization of the
key R132RL2:pT72 contacts through stacking interactions with
the side chain of R132RL2. More detailed analyses of a full-length
construct of RILPL2 and its affinity toward pRab8a is
described below.
In addition to RILPL2, key residues in switch 1 and the N
terminus of pRab8a were mutated to evaluate contributions
to complex formation (Figure 3B). Most mutations in Rab8a
tested likely disrupted protein stability, binding with other key
interactors or phosphorylation by LRRK2 and, therefore, it
was not possible to reliably evaluate the role of these residues
in RILPL2 interaction in vivo. However, Rab8a mutations T4AR8
and K58AR8 were still phosphorylated by LRRK2 and were able
to bind RILPL2, suggesting that these residues are not critical
for this interaction.
The hotspots for pRab8a:RILPL2 interactions, as gleaned from
cellular interactions with RILPL2 mutants, are shown with circles
above the sequences of RILP family proteins (Figure 3C). The red
circles denote essential residues for recognition of pRab8a(GTP)
and are mostly conserved in the phospho-Rab binding domains.
Arg139RL2 mutations have modest effects on Rab8a recognition
(Figures 3A and S3), and are not conserved (blue circle).
Pro131RL2 is variable in this family and the mutant Pro131ARL2
does not affect binding, suggesting that sequence variability is
possible within the X-cap.
GTP Dependency of the Interaction between pRab8a
and RILPL2
The GTP dependency of pRab8a interactions with full-length
RILPL2 were investigated using in vitro pull-downs (Figure 4A).
The interaction with RILPL2 in vitro is dependent on both the
GTP conformation and phosphorylated T72 for Rab8a. Non-
phosphorylated Rab8a and pRab8a(GDP) did not interact
measurably with RILPL2.
To further investigate the GTP dependency in cells, we co-ex-
pressed RILPL2 with either wild-type Rab8a, Rab8a[Q67L] (GTP
trapped conformation) or Rab8a[T22N] (GDP bound conforma-
tion) in the presence of pathogenic LRRK2[Y1699C] to induce
maximal Rab8a phosphorylation (Figures 4B and S4). For these
experiments, cells were treated ± LRRK2 MLi-2 inhibitor and
phosphorylation of wild-type and mutant Rab8a was assessed
in cell extracts as well as RILPL2 immunoprecipitates. Strikingly,
this revealed that both cell lysates and immunoprecipitates of the
pRab8a[Q67L] GTP locked mutant, MLi-2 failed to induce
dephosphorylation of Rab8a over a 90-min period (Figure 4B).
As mentioned previously, PPM1H has been identified as the
phosphatase that dephosphorylates Rab GTPases (Berndsen
et al., 2019). One interpretation of this observation is that the
pRab8a[Q67L] GTP locked conformation remains stably associ-
ated with RILPL2 over this period and is thus protected from
PPM1H. However, it cannot be excluded that PPM1H acts exclu-
sively on pRab8a(GDP) in the cytosol, although in vitro studies
demonstrated that PPM1H dephosphorylated pRab8a(GTP)
and pRab8a(GDP) with similar efficiency (Berndsen et al., 2019).
In comparison, MLi-2 treatment induced significant dephosphor-
ylation of wild-type Rab8a that is presumably interconverting
between the GTP and GDP conformation (Figure 4B). The GDP-
locked conformation of Rab8a[T22N] was expressed at much
lower levels in cell than wild-type or Rab8a[Q67L] (Figure S4).
Nevertheless, no association of RILPL2 with Rab8a[T22N] was
observed. Furthermore, phosphorylation of Rab8a[T22N] was
not observed which is consistent with the GTP bound conforma-
tion being regulated by LRRK2.
Binding of pRab8a to Full-Length RILPL2 Is Enhanced
by MyoVa
Relative to the isolated RH2 domain, all observed interactions
in vitro between pRab8a and full-length RILPL2 were weak and
unsuitable for isothermal titration calorimetry (e.g., Figure 4A).
However, in the presence of the GTD of MyoVa, we observed
a small but significant enhancement in affinity between pRab8a
and RILPL2. Therefore, we utilized pull-down assays to charac-
terize pRab8a:RILPL2 complex formation in the presence of
MyoVa (Figures 5 and S5). The binary interactions between
MyoVa and mouse RILPL2 have been measured previously
binder Sepharose and immunoprecipitates evaluated by immunoblotting with the indicated antibodies. Immunoblots were developed using the LI-COROdyssey
CLx western blot imaging system with the indicated antibodies at 0.5–1 mg/mL concentration. Lower panel, labeled input: 10 mg whole-cell lysate was subjected
to LI-COR immunoblot analysis. Each lane represents cell extract obtained from a different dish of cells. Similar results were obtained in two separate experi-
ments. (B) Same as A, but HEK293 cells were transiently transfected with WT or mutant HA-Rab8a as well as Flag-LRRK2[R1441G] and RILPL2-GFPWT. At 48 h
post transfection, cells were treated with ±500 nMMLi-2 for 90 min and then lysed. RILPL2-GFP was immunoprecipitated using GFP binder Sepharose and as in
(A), immunoprecipitates and input were evaluated by immunoblotting with the indicated antibodies. Each lane represents cell extract obtained from a different
dish of cells. Similar results were obtained in two separate experiments.
(C) Sequence alignment of the first a helix (a1) of the RILP family RH2 domains. Residues corresponding to the second a helix (a2) of RILP are not shown. Red
circles are hotspots for the interactions where mutations severely reduce affinity between pRab8a and RILPL2. Blue circles indicate residues that are tolerant to
mutations. The a-helical secondary structure above the alignment corresponds to RILPL2.
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(Kd = 0.3 mM; Wei et al., 2013), and are 10-fold stronger than
pRab8a interactions with the RH2 domain. In the presence of
MyoVa, there is a clear increase in affinity between pRab8a
and full-length RILPL2 (Figure 5A). This interaction is dependent
on phosphorylated T72, since Rab8a(GTP) does not interact with
the RILPL2:MyoVa complex. There are no observable interac-
tions between pRab8a/Rab8a and the GTD of MyoVa (Figures
5B and S5).
The pull-downs were quantified to show the relative increase
in binding of pRab8a:RILPL2 in the presence of MyoVa (Fig-
ure 5C). These data suggest that MyoVa(GTD) binding to the
RH1 domain of RILPL2 enhances the affinity between the RH2
domain and pRab8a. A model of RILPL2 was built using the
structure of the mouse RH1 domain (PDB: 4kp3) together with
the human RH1 domain (Figure 5D). The side-by-side ribbon
and electrostatic surface model shows that the two regions
have complementary charges separated by a 20-residue flexible
Figure 4. Evidence that RILPL2 Binds to the
GTP Bound Conformation of Phosphorylated
Rab8a in Cells
(A) Direct in vitro pull-downs were performed using
purified His6-tagged RILPL2 (full length) as bait and
untagged Rab8a as prey. Rab8a species were
either non-phosphorylated (Rab8a) or phosphory-
lated (pRab8a). The GTP forms were stabilized via
the Q67L mutation in switch 2. The GDP form of
Rab8a was prepared by in vitro exchange using
wild-type (WT) Rab8a before the phosphorylation
reaction to generate pRab8a(GDP). Protein con-
centrations were 10 mM for bait and prey, inputs are
2 mg; n R 3, Coomassie stain for visualization.
Dotted lines emphasize that only pRab8a(GTP)
binds to RILPL2.
(B) HEK293 cells were transiently transfected with
constructs expressing the indicated components.
24 h post transfection, cells were treated
with ±100 nM MLi-2 for 90 min and then lysed.
Upper panel, labeled IP:GFP: RILPL2-GFP was
immunoprecipitated using GFP binder Sepharose
and immunoprecipitates evaluated by immuno-
blotting with the indicated antibodies. Immunoblots
were developed using the LI-COR Odyssey CLx
western blot imaging system with the indicated
antibodies at 0.5–1 mg/mL concentration. Lower
panel, labeled input: 10 mg whole-cell lysate was
subjected to LI-COR immunoblot analysis. Each
lane represents cell extract obtained from a different
dish of cells. Similar results were obtained in two
separate experiments.
linker. In the absence of MyoVa, the RH1/
RH2 domains of RILPL2 could interact in
cis, thereby sterically blocking the X-cap
and reducing the affinity of RH2 for
pRab8a.
JIP3/4 Bind to LRRK2-
Phosphorylated Rab10
Sequence comparisons suggest that two
other scaffolding proteins previously impli-
cated in JNK signaling, namely JIP3 (gene
MAPK8IP3; Kelkar et al., 2000) and JIP4 (gene SPAG9; Kelkar
et al., 2005), likely possess a phospho-Rab binding domain.
These proteins have key residues equivalent to R130RL2,
R132RL2, and K149RL2 in their RH2 domain (Figure 3C). We,
therefore, tested whether full-length JIP3 or JIP4 would bind to
LRRK2-phosphorylated Rab8a or Rab10 in cells employing the
co-expression assay utilized above to assess interaction of
pRab8a with RILPL2 (Figures 6A and S6). These results revealed
that both JIP3 and JIP4 specifically associated with LRRK2-
phosphorylated Rab10. Addition of Mli-2 ablated interaction of
JIP3 and JIP4 with Rab10 consistent with the interaction being
phosphorylation dependent (Figure 6A). In contrast, a weak
interaction just above background was observed between
Rab8a and JIP3/4, which was not dependent upon phosphoryla-
tion by LRRK2 (Figure S6). This emphasizes that phospho-Rab
binding domains are likely to display selectivity for different
phosphorylated Rab proteins. Further work is required to identify
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which sets of phospho-Rab proteins interact with JIP3/4 and
how these complexes regulate cytoskeletal dynamics through
the microtubule network (Figure 6B).
DISCUSSION
The structure of the Rab binding domain of RILP bound to Rab7
has been determined previously (Figure 7A) (Wu et al., 2005).
Similar to RILPL2, the effector forms a parallel coiled coil that
binds two Rab7 molecules as a heterotetrameric complex.
RILP does not have an X-cap at the N terminus—the first few res-
idues in the structure beginning at Cys241 are disordered until
the start of the core helix at Glu246 (Figures 7A and 7B).
Following helix a1 of the Rab binding domain of RILP, a loop
brings a second antiparallel helix a2 back toward the a1 dimer
and is stabilized by hydrophobic interactions. Helix a2 is unlikely
to be conserved in RILPL1/2 given a string of glycine and proline
residues in these proteins following helix a1, which would be
disruptive to secondary structures (Figure 3C). Interestingly,
LRRK1 phosphorylation of Rab7 at Ser72 (switch 2) has recently
been shown to promote interactions with RILP (Hanafusa et al.,
2019). The RILP construct used for recombinant expression
begins at C241 and the PDB file (PDB: 1yhn) for the complex
RILP:Rab7 contains the coordinates for RILP beginning at
Figure 5. MyoVa Interactions with the RH1 Domain Enhance the Affinity of RILPL2 to pRab8a
(A) Pull-downs of (p)Rab8a and RILPL2 in the presence of MyoVa(GTD). Input proteins are in the upper left panel, while duplicate pull-downs are shown to the
right. Phosphorylated Rab8a (pRab8a) is highlighted in the pull-down lanes with red (+) labels. Bait and prey proteins were used at 2.5 mM.
(B) Control experiment showing that no interactions are observed between His6-tagged MyoVa and pRab8a/Rab8a.
(C) Quantification of densitometry readings of pRab8a pull-downs from three independent experiments (p < 0.005).
(D) Modeling of full-length RILPL2 using ribbons and electrostatic surfaces. The RH1 domain of mouse RILPL2 was connected to the RH2 domain of human
RILPL2. Residue numbers correspond to the human protein.
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S244 (T134RL2). It is possible that an X-cap could form and bind
to pSer72 (Rab7) given a modest extension of the RILP polypep-
tide toward the N terminus to stabilize backbone antiparallel
hydrogen bonds. Although RILP lacks a positive residue
(Q240), the structure of pRab8a:RILPL2 reveals that Arg130RL2
is distant frompThr72 andmay be tolerated as a glutamine within
a possible X-cap in the RILP:pRab7 complex.
Unphosphorylated Rab8a is a promiscuous small GTPase and
its structures in complex with effectors OCRL1 and MICAL have
also been determined. The inositol-5-phosphatase OCRL1 is
recruited to Rab8a membranes and regulates aspects of endo-
somal/Golgi trafficking (Mehta et al., 2014). Inherited X-linked
mutations in OCRL1 lead to oculocerebrorenal syndrome of
Lowe, which is associated with intellectual disability, cataracts,
and renal dysfunction. Pull-downs using endogenous and hem-
agglutinin-tagged Rab8a reveal that OCRL1 does not bind to
pRab8a (Steger et al., 2017). Superposition of the Rab8a:OCRL1
onto the pRaba:RILPL2 complex reveals a steric clash of non-
Figure 6. Evidence that JIP3 and JIP4 Bind to
LRRK2-Phosphorylated Rab10 in Cells
(A) HEK293 cells were transiently transfected with
constructs expressing the indicated components. At
24 h post transfection, cells were treated with ±100 nM
MLi-2 for 90 min and then lysed. Upper panel, labeled
IP:GFP: RILPL2-GFP, JIP3-GFP, JIP4-GFP were
immunoprecipitated using GFP binder Sepharose and
immunoprecipitates evaluated by immunoblotting with
the indicated antibodies. Immunoblots were devel-
oped using the LI-COR Odyssey CLx western blot
imaging system with the indicated antibodies at
0.5–1 mg/mL concentration. Lower panel, labeled
input: 10 mgwhole-cell lysatewas subjected to LI-COR
immunoblot analysis. Each lane represents cell extract
obtained from a different dish of cells. Similar results
were obtained in two separate experiments.
(B) Domain organization of JIP3 and JIP4. Sequence
numbers correspond to JIP3, the interacting partners
are shown above the cartoon, and p150G refers to
p150Glued. The figure is adapted from the recent
structure of the RH1-LZI domain of JIP3 (Vilela et al.,
2019). KHC, kinesin heavy chain; KLC, kinesin light
chain; DLIC, dynein light intermediate chain.
hydrogen atoms between switch 2 and
OCRL1 (Figures 7C and 7D). Switch 2 phos-
phorylation also disrupts interactions
between Rab8a and GDI as well as Rabin8,
a GEF for Rab8a (Steger et al., 2016). Along
with GAPs, these Rab modulators interact
with a broad segment of the switch 1/2 inter-
face and would clash with pT72. In contrast
to OCRL1, the effector MICAL can be
docked onto pRab8a without steric prob-
lems (data not shown). Parallel coiled coils
as Rab binding motifs are commonly ex-
ploited by effectors for membrane trafficking
(Khan and Menetrey, 2013). However, the
RILPL2-RH2 motif described here adopts a
unique X-cap structure that resembles a
short antiparallel b sheet at the N terminus
of the coiled coil. The conformation enables positioning of Arg
residues that recognize the phosphate on switch 2. The X-cap
is likely a conserved feature among the RILP and JIP family of
effector proteins.
Amodel forLRRK2control ofRab trafficking isshown inFigure8.
Recent in vitro and cellular data are consistent with active
Rab29(GTP) recruitment of the effector LRRK2 onto membranes
where it phosphorylates substrates, such as Rab8a (Gomez
et al., 2019;McGrath et al., 2019). The post-translationalmodifica-
tion is situated at the edge of the switch/interswitch region of
pRab8a and facilitates tuning of the strength of interacting pro-
teins, including effectors, GAPs, GEFs, and GDI. The phospho-
specific effector, RILPL2, is recruited onto membranes possibly
as a preformed complex with MyoVa. Autosomal dominant vari-
ants of LRRK2 enhance the levels of pRab10 up to a maximum
of4%of totalRab10 incells,which isamodest2- to4-fold increase
over basal phosphorylation (Ito et al., 2016; Karayel et al., 2019).
The effects arising from a small change in LRRK2-phosphorylated
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Rabs may be amplified through several mechanisms. One is the
inability of Rabs to interact with GAPs, thereby prolonging the life-
timeofpRabsonmembranes.Asecondmechanism is recruitment
of phospho-specific RILPL1/2 at the expense of other effectors,
such as OCRL1. Here, we demonstrate that MyoVa enhances
the affinity between pRab8a and RILPL2. In addition, a region of
MyoVa encoded by exon D, ahead of the C-terminal GTD, also in-
teracts directly with Rab8a and Rab10 (Lindsay et al., 2013).
Finally, the ternary complex of pRab8a:RILPL2:MyoVa may be
resistant to PPM1H-mediated hydrolysis of pT72. Together these
factors could partly explain howLRRK2directs pRab8a/10 toward
RILPL1/2-associated ciliary trafficking pathways.
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STAR+METHODS
KEY RESOURCES TABLE
REAGENT or RESOURCE SOURCE IDENTIFIER
Antibodies
Rabbit anti LRRK2 N-term University of Dundee UDD3
Rabbit anti GFP Chromotek PABG1
Rabbit anti GFP Cell Signaling Technology #2956
Rat anti HA Merck 3F10
Rabbit anti-pT72-Rab8a Abcam MJF-R20; ab231706
Mouse anti LRRK2 C-term NeuroMAB N241A/34; AB_10675136
Mouse anti Tubulin Cell Signaling Technology 3873S
Mouse anti GAPDH Santa Cruz Biotechnology sc-32233
Goat anti-Rabbit IRDye 800CW Licor 925-32211
Goat anti-Mouse IRDye 800CW Licor 926-32210
Goat anti-Rat IRDye 680LT Licor 925-68029
Goat anti-mouse IRDye 680LT Licor 926-68020
Goat anti-Rat IgG HRP conjugated Thermo Fisher Scientific #31470
Bacterial and Viral Strains
E. coli BL21 (DE3) New England Biolabs C2527
E. coli DH5a New England Biolabs C2987
Chemicals, Peptides, and Recombinant Proteins
His6-RILPL2 residue 129-165 Genscript N/A
GDP Sigma Aldrich G7127
ATP Sigma Aldrich A2383
MIL-2 LRRK2 inhinbitor MRC PPU Reagents Services N/A
GST-MST3 MRC PPU Reagents Services DU30889
Polyethylenimine PEI Polysciences 23966
aGFP binder sepharose MRC PPU Reagents Services N/A
PhosTag reagent MRC PPU Reagents Services N/A
Ni-agarose fast flow GE Healthcare 17531802
Critical Commercial Assays
JCSG-plus crystallography screen Molecular Dimensions MD1-37
PACT premier crystallography screen Molecular Dimensions MD1-29
Isolate II Miniprep Kit Bioline BIO-52057
Deposited Data
pRab8a:RILPL2 complex This study PDB: 6RIR
Rab7:RILP complex Wu et al., 2005 PDB: 1YHN
Strcture of Rab8a:OCRL1 complex Hou et al., 2011 PDB: 3QBT
MyosinVa GTD:RILPL2 complex Wei et al., 2013 PDB: 4KP3
Experimental Models: Cell Lines
HEK293 ATCC CRL-1573
Oligonucleotides
Rab8a mutagenesis primer for GG GAT ACC
GCG GGT CAG GAA CGT TTT CGT AC
This study N/A
Rab8a mutagenesis primer rev GT ACG AAA
ACG TTC CTG ACC CGC GGT ATC CC
This study N/A
(Continued on next page)
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Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Recombinant DNA
pET28a(+)-Rab8a1-181Q67L Genscript N/A
pET28a(+)-Rab8a1-181WT This study N/A
pET15b-RILPL2 Genscript N/A
pET28a(+)-MyosinVa GTD Genscript N/A
pCVM5 HA-empty MRC PPU Reagents Services DU49303
pcDNA5 GFP-empty MRC PPU Reagents Services DU13156
pCMV Flag-LRRK2 R1441G MRC PPU Reagents Services DU13077
pCMV Flag-LRRK2 Y1699C MRC PPU Reagents Services DU1316
pCMV HA-Rab8a WT MRC PPU Reagents Services DU35414
pCMV HA-Rab10 WT MRC PPU Reagents Services DU44250
pcDNA5D FRT/TO RILPL2-GFP WT MRC PPU Reagents Services DU27481
pcDNA5D FRT/TO RILPL2-GFP R130K MRC PPU Reagents Services DU68258
pcDNA5D FRT/TO RILPL2-GFP R130A MRC PPU Reagents Services DU68022
pcDNA5D FRT/TO RILPL2-GFP R130Q MRC PPU Reagents Services DU27521
pcDNA5D FRT/TO RILPL2-GFP R130E MRC PPU Reagents Services DU27520
pcDNA5D FRT/TO RILPL2-GFP P131A MRC PPU Reagents Services DU68030
pcDNA5D FRT/TO RILPL2-GFP P131C MRC PPU Reagents Services DU68031
pcDNA5D FRT/TO RILPL2-GFP P131K MRC PPU Reagents Services DU68256
pcDNA5D FRT/TO RILPL2-GFP P131R MRC PPU Reagents Services DU68257
pcDNA5D FRT/TO RILPL2-GFP R132K MRC PPU Reagents Services DU68023
pcDNA5D FRT/TO RILPL2-GFP R132A MRC PPU Reagents Services DU67110
pcDNA5D FRT/TO RILPL2-GFP R132Q MRC PPU Reagents Services DU68037
pcDNA5D FRT/TO RILPL2-GFP R132E MRC PPU Reagents Services DU27522
pcDNA5D FRT/TO RILPL2-GFP F133A MRC PPU Reagents Services DU68033
pcDNA5D FRT/TO RILPL2-GFP L135A MRC PPU Reagents Services DU68032
pcDNA5D FRT/TO RILPL2-GFP R139A MRC PPU Reagents Services DU68025
pcDNA5D FRT/TO RILPL2-GFP R139Q MRC PPU Reagents Services DU68024
pcDNA5D FRT/TO RILPL2-GFP R139E MRC PPU Reagents Services DU68026
pcDNA5D FRT/TO RILPL2-GFP K149A MRC PPU Reagents Services DU68029
pcDNA5D FRT/TO RILPL2-GFP K149Q MRC PPU Reagents Services DU68027
pcDNA5D FRT/TO RILPL2-GFP K149E MRC PPU Reagents Services DU68028
pcDNA5D FRT/TO RILPL2-GFP E157A MRC PPU Reagents Services DU68036
pcDNA5D FRT/TO RILPL2-GFP E157Q MRC PPU Reagents Services DU68034
pcDNA5D FRT/TO RILPL2-GFP E157K MRC PPU Reagents Services DU68035
pCMV HA-Rab8a Q67L MRC PPU Reagents Services DU39393
pCMV HA-Rab8a T22N MRC PPU Reagents Services DU39392
pCMV5 HA-Rab8a T4A MRC PPU Reagents Services DU68045
pCMV5 HA-Rab8a D44A MRC PPU Reagents Services DU68041
pCMV5 HA-Rab8a D44N MRC PPU Reagents Services DU68039
pCMV5 HA-Rab8a D44K MRC PPU Reagents Services DU68040
pCMV5 HA-Rab8a K58A MRC PPU Reagents Services DU68044
pCMV5 HA-Rab8a K58Q MRC PPU Reagents Services DU68042
pCMV5 HA-Rab8a K58E MRC PPU Reagents Services DU68043
pcDNA5D FRT/TO JIP3-GFP MRC PPU Reagents Services DU27721
pcDNA5D FRT/TO JIP4-GFP MRC PPU Reagents Services DU27684
pcDNA5D FRT/TO RILPL1-GFP MRC PPU Reagents Services DU27305
pCVM5 HA-empty MRC PPU Reagents Services DU49303
(Continued on next page)
e2 Structure 28, 1–12.e1–e6, April 7, 2020
Please cite this article in press as: Waschb€usch et al., Structural Basis for Rab8a Recruitment of RILPL2 via LRRK2 Phosphorylation of Switch 2, Struc-
ture (2020), https://doi.org/10.1016/j.str.2020.01.005
LEAD CONTACT AND MATERIALS AVAILABILITY
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METHOD DETAILS
Protein Expression and Purification
The cDNA for Rab8a (residues 1-181, Q67L) lacking the flexible C-terminal tail was ordered fromGenscript in a codon-optimized form
to enable E.coli expression. The cDNA was cloned into pET28a at the NdeI/BamH1 sites for both of these constructs. The Rab8a
wildtype (WT) construct was made by site directed mutagenesis using the following primers: 5’-GG GAT ACC GCG GGT CAG
GAA CGT TTT CGT AC-3’ (for) and: 5’-GT ACG AAA ACG TTC CTG ACC CGC GGT ATC CC-3’ (rev). Expression was carried out
in 2xYT Broth supplemented with 34 mg/ml kanamycin (FORMEDIUM) at 37C. At an OD600 of 0.7 the culture was induced with
0.5 mM IPTG (FORMEDIUM), after which cells were grown for a further 4 hours at 37C or 18C overnight. Cells were harvested
by centrifugation and the pellets were resuspended in His-tag extraction buffer (20 mM Tris-HCl, 300 mM NaCl, 5 mM MgCl2,
20 mM imidazole and 10 mM b-mercaptoethanol, pH 8.0) along with 0.5 mM PMSF protease inhibitor (Sigma). Cells were lysed
by sonication and the cell lysate was centrifuged at 26,000 x g for 45 minutes at 4C to remove cellular debris. The supernatants
were filtered and loaded onto a nickel agarose resin (QIAGEN). The resin was washed with a 10-fold excess of extraction buffer
and 5-fold excess wash buffer (extraction buffer supplemented with 40mM Imidazole). The protein was eluted using extraction buffer
supplemented with 200 mM imidazole.
Removal of the His6-tag (Rab8a) was performed by overnight incubation at 4
C with thrombin (GE Healthcare), followed by a
second Ni2+-agarose column. The ‘flow-through’ fractions were collected, while the uncut proteins remained on the resin. Soluble
aggregates were eliminated by running the sample through a Superdex 75 (16/60) gel filtration column (GE Healthcare) equilibrated
in column buffer (20 mM Tris-HCl, 100 mM NaCl, 5 mMMgCl2, 1 mM DTT, pH 7.5). A peptide corresponding to residues 129-165 of
RILPL2 was synthesized with an N-terminal hexahistidine tag (His6-RILPL2, Genscript). The peptide was solubilized in matching
buffer with Rab (20 mM Tris-HCl, 100 mM NaCl, 5 mM MgCl2, 1 mM DTT, pH 7.5) prior to crystallization trials and calorimetry.
The cDNA for full-length RILPL2 (1-211) and the GTD of myosin Va (1462-1853), optimized for E.coli expression, were obtained
from Genscript. The cDNAs were each synthesized with a 5’ NdeI extension and a 3’ extension comprising 2xSTOP codons
(TAA-TGA) followed by a BamH1 site. The cDNA for RILPL2 was subcloned into the Nde/Bam site of pET15b, while the cDNA for
Continued
REAGENT or RESOURCE SOURCE IDENTIFIER
Software and Algorithms
Phenix Liebschner et al., 2019 https://www.phenix-online.org/
Coot Emsley et al., 2010 https://www2.mrc-lmb.cam.ac.uk/personal/
pemsley/coot/
CCP4i Krissinel and Henrick, 2004; Winn et al., 2011 https://www.ccp4.ac.uk/ccp4i_main.php
PyMol Schro¨dinger, LLC https://pymol.org
ImageJ (Fiji) Schindelin et al., 2012 https://imagej.nih.gov/ij/
XDS Kabsch, (2010) http://xds.mpimf-heidelberg.mpg.de/
Aimless Evans and Murshudov, 2013 http://www.ccp4.ac.uk/html/aimless.html
Phaser McCoy et al., 2007 http://www.ccp4.ac.uk/html/phaser.html
Other
Superdex 75 (16/60) GE Healthcare 28-9893-33
Superdex 200 (16/60) GE Healthcare 28-9893-35
Superdex 75 (10/300) GE Healthcare 17-5174-01
Superdex 200 (10/300) GE Healthcare 17-5175-01
MonoS 5/50 GL GE Healthcare 17-5168-01
PD10 column GE Healthcare 17-0851-01
ITC-200 instrument Malvern Panalytical N/A
miniDAWN system SLS instrument Wyatt Corp N/A
Optilab rEX refractometer Wyatt Corp N/A
ZORBAX 300SB-C18 HPLC column Agilent N/A
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MyoVa(GTD) was subcloned into the identical site in pET28b. Expression and purification of these proteins were performed as
described for Rab8a above, except that the polyhistidine tag was not removed from RILPL2 for the pulldown experiment.
Rab8a Nucleotide Exchange
For the pulldownwith full-length RILPL2, nucleotide exchange was performed using purifiedWTRab8a incubated in 10mMEDTA for
10 minutes at room temperature in the presence of 10X molar excess GDP. The exchange was terminated by addition of 15 mM
MgCl2 and excess nucleotides were removed by running samples through a PD10 column (GE healthcare), or by immediate gel filtra-
tion chromatography. To verify successful exchange, 100 mL the protein (>1mg/mL) was boiled for 10 min at 95C to denature the
protein and release the nucleotide, followed by centrifugation for 30 min 16,000 x g, 4C to remove precipitated protein. The super-
natant was mixed with running buffer (100 mM potassium phosphate, 8 mM thiobarbituric acid, pH 6.5) at a 1:1 ratio. The samples
were loaded on an Acquity Ultra Performance system (Waters Corporation, Milford, MA, USA; or Varian 920 LC machine, Agilent,
Stockport, UK) equipped with a ZORBAX 300SB-C18 column (Agilent, Stockport, UK). Elution profiles of GMP, GDP, GTP (Sigma
Aldrich) and GppNHp (Jena Bioscience, Germany) were subjected to HPLC and compared with Rab8a. The nucleotide state of
Rab8a(Q67L) was confirmed to be GTP-bound using the analytical HPLC strategy.
In Vitro Kinase Assays
It has recently been shown that the MST3 kinase can specifically and efficiently phosphorylate Rab8a at Thr72 in vitro (Vieweg et al.,
2019). As MST3 is much easier to express than LRRK2, we decided to phosphorylate Rab8a at T72 using recombinant MST3. For
comparison of Rab8a phosphorylation by LRRK2 and MST3, kinase assays were performed with shaking at 30oC for 3h with molar
concentrations as indicated of 970-end length LRRK2 WT or G2019S (PV4873 and PV4882 respectively, ThermoFisher) or GST-
MST3 (supplied by MRC Reagents and Services, DU30889) and 2 mM of Rab8a 1-181 Q67L or Q67L+T72E as a negative control.
The kinase reaction buffer is 50 mM Tris-HCl pH 7.5, 10 mMMgCl2, 150 mM NaCl, 2 mM ATP. Efficiency of Rab8a phosphorylation
was compared using PhosTag gel electrophoresis and immunoblotting with Rab8a-pT72 antibody (Figure S1).
Phosphorylation of Rab8a
Full length GST-MST3 produced in insect cells (DU30889) was obtained from MRC-PPU Reagents and Services (https://
mrcppureagents.dundee.ac.uk/reagents-proteins/overview). Rab8a was incubated with GST-MST3 at molar ratios between 4:1
to 9:1 (substrate:enzyme). Typical concentrations of Rab8a were 1-3 mg/ml, while the concentration of MST3 was 1 mg/ml in a total
volume between 2-15ml. The buffer of the reaction was adjusted to 50mMTris-HCl, 150mMNaCl, 10mMMgCl2 and 2mMATP, pH
7.5. The reaction mixture was incubated at room temperature overnight (12-18 hours). To separate pRab8a from the non-phosphor-
ylated form, the reaction mixture was dialyzed against low-salt ion exchange buffer (10 mMMES, 10 mM NaCl, 5 mMMgCl2, 1 mM
DTT, pH 5.2) for two hours and then loaded onto aMonoS 5/50 GL column (GE Healthcare) equilibrated to the low-salt ion-exchange
buffer. Elution of pRab8a was performed by running a 50% gradient from low- to high-salt buffer (10 mM MES, 1 M NaCl, 5 mM
MgCl2, 1 mM DTT, pH 5.2) over 30 column volumes (Figure S2). The phosphorylation of Rab8a1-181 was confirmed by PhosTag
gel electrophoresis. In order to stabilize pRab8a, the pH was adjusted to pH 7.5 immediately after elution from the ion-exchange
column.
Crystallization, Data Collection and Refinement
Crystals of pRab8(Q67L): His6-RL2 complexwere obtained in a 1:1molar ratio of protein:peptide at a total of 12mg/mL. Crystals were
grown in 100 mM HEPES buffer (pH 7), 10% PEG4,000, and 10% 2-propanol. Plate-like crystals were harvested in precipitant sup-
plemented with 25% glycerol and stored frozen in liquid nitrogen. X-ray data were collected under a cryogenic nitrogen stream at
100K (beamline 24-ID-C, Advanced Photon Source).
Native diffraction data were reduced using XDS and aimless, followed by structure determination using the Phaser software in the
PHENIX package (Adams et al., 2010; McCoy et al., 2007). Initial rounds of molecular replacement using Rab8a [GppNHp, PDB code
4lhw; (Guo et al., 2013)] resulted in a solution for 2 molecules in the asymmetric unit. Following successful identification of Rab8a in
the crystal lattice, the electron density for the coiled coil of the effector was apparent. Side chains for RILPL2 were clear in the initial
electron density, and refinement was performed using multiple rounds of model building and energy minimization using PHENIX and
COOT (Emsley et al., 2010). The asymmetric unit contains two molecules of Rab8a (A:4-176, B:2-176) bound to GTP and a magne-
sium ion, and twomolecules of the effector (C:129-159, E:129-160). The hexahistidine tag at the N-termini of the effector is not seen in
electron density maps, except for one histidine at the N-terminus of chain C. Comprehensive validation, including MolProbity, was
performed during the refinement process to gauge the quality of the model (Williams et al., 2018). Statistics of the data collection and
refinement are shown in Table 1.
Structural Analyses and Superpositions
In general, structures were aligned using the ‘secondary structure matching’ (SSM) protocol in COOT. The backbone superpositions
of Rab8a from multiple structures (complexed, uncomplexed) typically aligned with an RMSD of 0.4 A˚. The heterotetrameric struc-
tures of Rab8a:RILPL2 and Rab7:RILP were aligned using the Superpose software in CCP4 (Krissinel and Henrick, 2004; Winn et al.,
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2011). In order to better visualize the relative positions of the effectors, secondary structures from all 4 molecules in each complex
were aligned. A total of 330 residues werematched, including 21 residues from each chain of RILP and RILPL2. The overall RMSD for
the backbone atoms was approximately 3 A˚.
Pulldown Assays, Isothermal Titration Calorimetry, and Static Light Scattering
Calorimetry was performed in triplicate on an ITC-200 instrument (Malvern Panalytical). Protein concentrations were calculated
based on their Abs280 using a ND-1000 NanoDrop spectrophotometer (Thermo Scientific). Following purification of Rab8a, the pro-
tein was dialyzed together in the same buffer as RILPL2 (10 mM Tris-HCl, 300 mM NaCl, 5 mM MgCl2, 20 mM imidazole and 1 mM
DTT). Samples were centrifuged at 13,200 rpm for 10 minutes prior to concentration determination and ITC analysis. The concentra-
tions of proteins for injections were between 400-600 mM (His6-RILPL2, residues 129-165) and 40-60 mMRab8a and pRab8a (1-181).
For in vitro pulldowns, full-length RILPL2 (1-211) and the GTD of myosin Va (residues 1462-1853) were used. Rabs, RILPL2, and
MyoVa (GTD) were mixed together in 1.5 mL centrifuge tubes at final concentrations ranging from 2.5-10 mMwith 25 ml Ni2+- agarose
resin in a final volume of 1ml of binding buffer (20 mM Tris pH 8.0, 300 mM NaCl, 20 mM imidazole, 5 mM MgCl2, 10 mM b-merca-
potoethanol). The reaction mixture was subjected to mild shaking for 15 minutes. Following gentle centrifugation (1,000 rpm), the
resin was washed 3 times with 1 ml of the binding buffer. Following release of proteins from resin with 50 ml elution buffer (20 mM
Tris-Cl pH 8.0, 300 mM NaCl, 200 mM imidazole), samples were subjected to SDS-PAGE and visualization with 0.5% Coomassie
Brilliant Blue. Quantification of pulldowns was carried out using the Gel analyzer function of ImageJ(Schindelin et al., 2012), and sta-
tistical analyses were done using Microsoft Excel, version 15.28.
Static light scattering coupled to gel filtration was performed using aminiDAWN system (Wyatt Corp), anOptilab rEX refractometer,
and a Superdex 200 (10/300) column. Full-length RILPL2 with an uncleaved polyhistidine tag was used, and 500mL was injected at a
concentration of 1mg/mL. Data were processed using Astra software version 5.3.
Plasmids for Cellular Assays
The plasmids used for co-immunoprecipitation experiments were acquired from MRC PPU Reagents and Services (https://
mrcppureagents.dundee.ac.uk/reagents-proteins/overview): HA-empty pCVM5 (DU49303); GFP-empty pcDNA5 (DU13156);
Flag-LRRK2 R1441G pCMV (DU13077); Flag-LRRK2 Y1699C pCMV (DU13165); HA-Rab8a WT pCMV (DU35414); HA-Rab10 WT
pCMV (DU44250); RILPL2-GFP WT pcDNA5D FRT/TO (DU27481); RILPL2-GFP R130K pcDNA5D FRT/TO (DU68258), RILPL2-
GFP R130A pcDNA5D FRT/TO (DU68022); RILPL2-GFP R130Q pcDNA5D FRT/TO (DU27521); RILPL2-GFP R130E pcDNA5D
FRT/TO (DU27520); RILPL2-GFP P131A pcDNA5D FRT/TO (DU68030); RILPL2-GFP P131C pcDNA5D FRT/TO (DU68031);
RILPL2-GFP P131K pcDNA5D FRT/TO (DU68256), RILPL2-GFP P131R pcDNA5D FRT/TO (DU68257) RILPL2-GFP R132K
pcDNA5D FRT/TO (DU68023); RILPL2-GFP R132A pcDNA5D FRT/TO (DU67110); RILPL2-GFP R132Q pcDNA5D FRT/TO
(DU68037); RILPL2-GFP R132E pcDNA5D FRT/TO (DU27522); RILPL2-GFP F133A pcDNA5D FRT/TO (DU68033); RILPL2-GFP
L135A pcDNA5D FRT/TO (DU68032); RILPL2-GFP R139A pcDNA5D FRT/TO (DU68025); RILPL2-GFP R139Q pcDNA5D FRT/TO
(DU68024); RILPL2-GFP R139E pcDNA5D FRT/TO (DU68026); RILPL2-GFP K149A pcDNA5D FRT/TO (DU68029); RILPL2-GFP
K149Q pcDNA5D FRT/TO (DU68027); RILPL2-GFP K149E pcDNA5D FRT/TO (DU68028); RILPL2-GFP E157A pcDNA5D FRT/TO
(DU68036); RILPL2-GFP E157Q pcDNA5D FRT/TO (DU68034); RILPL2-GFP E157K pcDNA5D FRT/TO (DU68035), HA-Rab8a
Q67L pCMV (DU39393), HA-Rab8a T22N pCMV (DU39392), HA-Rab8a T4A pCMV5 DU68045), HA-Rab8a D44A pCMV5
(DU68041), HA-Rab8a D44N pCMV5 (DU68039), HA-Rab8a D44K pCMV5 (DU68040), HA-Rab8a K58A pCMV5 (DU68044), HA-
Rab8a K58Q pCMV5 (DU68042), HA-Rab8a K58E (DU68043), JIP3-GFP pcDNA5D FRT/TO (DU27721), JIP4-GFP pcDNA5D FRT/
TO (DU27684), RILPL1-GFP pcDNA5D FRT/TO (DU27305).
Antibody Reagents
Antibodies used in this study were diluted in 5% w/v bovine serum albumin in TBS supplemented with 0.1% Tween-20 and 0.03%
w/v sodium azide. The Rabbit monoclonal antibody for total LRRK2 (N-terminus) was purified at the University of Dundee (Dzamko
et al., 2012). Anti-GFP (PABG1, Chromotek, used at 1:1000) anti-GFP (#2956, CST, used at 1:1000), anti-HA (3F10, Merck, used at
1:1000), anti-pT72-Rab8a (MJF-R20, Abcam, used at 0.5 mg/mL), anti-LRRK2 C-terminal (N241A/34, Neuromab, used at 1:1000),
and anti-aTubulin (3873S, CST, used at 1:5000), anti-GAPDH (#sc-32233, Santa Cruz Biotechnology, used at 1:5000). Secondary
antibodies used were Licor IRDye for 800CW goat anti-rabbit (925-32211), goat anti-mouse (926-32210) and 680LT goat anti-rat
(925-68029) and goat anti-mouse (926-68020), all used at 1:10,000 dilution in TBS with 0.1% v/v Tween-20 (TBS-T) and horseradish
peroxidase-conjugated rat IgG secondary antibody (#31470, Thermo Fisher Scientific) used at 1:10,000 dilution in 5% non-fat dry
milk dissolved in TBS-T.
Culture and Transfection of Cells
HEK293 cells were cultured in Dulbecco’s modified Eagle medium (Glutamax, Gibco) supplemented with 10% fetal bovine serum
(FBS, Sigma), 100 U/ml penicillin and 100 mg/ml streptomycin. Transient transfections were performed 40-48 hr prior to cell lysis us-
ing polyethylenimine PEI (Polysciences) at around 60-70% confluence. Transfections for co-immunoprecipitation experiments were
done in 10 cm round cell culture dishes using 3 mg of Flag-LRRK2 R1441G or Flag-LRRK2 Y1699C as indicated, 1 mg of HA control or
HA-Rab8a or HA-Rab10 and 1 mg of GFP control, RILPL2-GFP or JIP3/4-GFP cDNA construct per dish diluted in 1 mL of OPTIMEM
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media and supplemented with 20 mg of PEI and incubated for 20 min before being added to the cell media. 1 h before lysis cells were
treated with 500 nM of MLI-2 inhibitor or 0.1% DMSO control. Lysates were clarified by centrifugation at 17,000 x g for 10 min.
Co-Immunoprecipitation of Rab GTPases and RILPL2, JIP3 and JIP4
Cells were washed with PBS and lysed in lysis buffer - 50 mM Tris-HCl pH 7.5, 1 mM EGTA, 10 mM sodium b-glycerophosphate,
50 mM sodium fluoride, 5 mM sodium pyrophosphate*10H2O, 0.27 M sucrose and supplemented fresh before lysis with 1% v/v
Triton-x100, 1 tablet of cOmplete Mini (EDTA-free) protease inhibitor (Merck, 11836170001) per 10 mL of buffer, 0.1 mg/mL of micro-
cystin and 1 mM of sodium orthovanadate.
For GFP immunoprecipitation, lysates were incubated with nanobody aGFP binder sepharose fromMRC PPU Reagents and Ser-
vices for 1 hr (15 ml of packed resin/0.5 mg of lysate). Bound complexes were recovered by washing the beads three times with wash
buffer (50 mM Tris-HCl pH 7.5, 150 mM NaCl) before eluting with 2xSDS/PAGE sample buffer supplemented with 1% v/v 2-mercap-
toethanol. The samples were denatured at 70C for 10 min and the resin was separated from the sample by centrifugation through a
0.22 mm Spinex column (CLS8161, Sigma).
Gel Electrophoresis and Immunoblot Analysis
Samples were run on gels consisting of a 4% w/v acrylamide stacking gel [4% w/v acrylamide, 0.125 M Tris-HCl pH 6.8, 0.2% v/v
Tetramethylethylenediamine (TEMED) and 0.08% w/v ammonium persulphate (APS)] and 10% w/v acrylamide separating gel [10%
w/v acrylamide, 0.375MBis-Tris pH 6.8, 1% v/v tetramethylethylenediamine (TEMED) and 0.05%w/v ammonium persulphate (APS)]
in MOPS buffer (50 mMMOPS, 50mM Tris, 1 mMEDTA, 0.1%w/v SDS) at 90-120 V. For Coomassie staining, gels were stained with
InstantBlue Ultrafast Protein Stain (ISB1L, Sigma-Aldrich) according to the manufacturer’s instructions and the gels were imaged
using LICOR Odyssey CLx. For immunoblot analysis, proteins were electrophoretically transferred onto nitrocellulose membranes
(Amersham Protran 0.45 mm NC; GE Healthcare) at 90 V for 90 min on ice in transfer buffer [48 mM Tris/HCl, 39 mM glycine, 20%
v/v methanol]. Transferred membranes were blocked with 5% w/v non-fat dry milk dissolved in TBS-T [20 mM Tris/HCl, pH 7.5,
150 mM NaCl and 0.1% v/v Tween 20] at room temperature for 1 h. Membranes were then incubated with primary antibodies over-
night at 4C. After washing membranes in TBS-T 3x15 min, membranes were incubated with secondary antibodies at room temper-
ature for 1 h. After washing membranes in TBS-T 3x15 min membranes were scanned using LICOR Odyssey CLx.
PhosTag Gel Electrophoresis and Immunoblot Analysis
Samples were supplementedwith 10mMMnCl2 before loading gels. Gels for Phos-tag SDS/PAGE consisted of a stacking gel [4%w/
v acrylamide, 0.125 M Tris/HCl, pH 6.8, 0.2% v/v tetramethylethylenediamine (TEMED) and 0.08% w/v ammonium persulfate APS]
and a separating gel [10% w/v acrylamide, 375 mM Tris/HCl, pH 8.8, 75 mM PhosTag reagent (MRC PPU Reagents and Services),
150 mMMnCl2, 0.1% v/v TEMED and 0.05%w/v APS]. After centrifugation at 17,000 x g for 1 min, samples were loaded and electro-
phoresed at 90 V with the running buffer [25 mM Tris/HCl, 192 mM glycine and 0.1% w/v SDS]. For Coomassie staining, gels were
stained with InstantBlue Ultrafast Protein Stain (ISB1L, Sigma-Aldrich) according to the manufacturer’s instructions and the gels
were imaged using LICOR Odyssey CLx. For immunoblot analysis, gels were washed 3x10 min in 48 mM Tris/HCl, 39 mM glycine,
10 mM EDTA and 0.05% w/v SDS followed by one wash in 48 mM Tris/HCl, 39 mM glycine and 0.05% w/v SDS for 10 min. Proteins
were electrophoretically transferred onto nitrocellulose membranes (Amersham Protran 0.45 mm NC; GE Healthcare) at 100 V for
180 min on ice in transfer buffer [48 mM Tris/HCl, 39 mM glycine, 20% v/v methanol]. Transferred membranes were blocked with
5% w/v non-fat dry milk dissolved in TBS-T [20 mM Tris/HCl, pH 7.5, 150 mM NaCl and 0.1% v/v Tween 20] at room temperature
for 1 h. Membranes were then incubated with primary antibodies overnight at 4C. After washing membranes in TBS-T 3x15 min,
membranes were incubated with horseradish peroxidase labelled secondary antibody diluted in 5% skimmed milk powder in
TBS-T at room temperature for 1 h. After washing membranes in TBS-T (5x10 mins), protein bands were detected by exposing films
(Amersham Hyperfilm ECL, GE Healthcare) to the membranes using an ECL solution (SuperSignal West Dura Extended Duration,
Thermo Fisher Scientific).
DATA AND CODE AVAILABILITY
The coordinates for the structure of the pRab8a:RILPL2 complex have been deposited in the Protein Data Bank with accession code
6RIR. PDB codes 4LHW, 4KP3, and 1YHN were referenced in this study.
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